Sort
10,766 grants matching “checkpoint inhibitor”
Characterization of the BRCT-mediated ATRIP recruitment
$50,428Andrew R Snyder · Wistar Institute · F32 · FY2007 · CA
A polymorphism in the Mdm2 promoter enhances cancer risk
$50,428Sean M Post · University Of Tx Md Anderson Can Ctr · F32 · FY2006 · CA
Development of Immunotherapy for Medullary Thyroid Cancer
$50,278Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Project 1: Developing immune checkpoint controlled-release biomaterials for cancer immunotherapy
$50,237Todd D Giorgio · Vanderbilt University Medical Center · U54 · FY2023 · CA
Diversity Supplement - TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
$50,133Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Targeting mechanisms of chromatin plasticity to improve the efficacy of epigenetic solid tumor therapy
$50,038Yanqing Liu · Van Andel Research Institute · F99 · FY2025 · CA
Therapeutic and Sustained Cytokine Delivery at the Tumor Site Using Engineered Mononuclear Cells
$50,016Patrick Sean Donahue · Northwestern University · F30 · FY2019 · CA
Balancing Efficacy and Toxicity of Intratumoral Reolysin for Diffuse Intrinsic Pontine Glioma (DIPG)
$50,016Matthew Schuelke · Mayo Clinic Rochester · F30 · FY2019 · CA
B7x in Cancer: Mechanisms and Therapies
$50,016Peter John · Albert Einstein College Of Medicine · F30 · FY2019 · CA
Meningeal lymphangiogenesis effect on malignancy ofglioblastoma.
$50,016Hoyeon Eric Song · Yale University · F30 · FY2019 · CA
Function of IRF8 in T cell activation and immune tolerance
$50,016John David Klement · Augusta University · F30 · FY2019 · CA
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition
$50,016Daniel R Principe · University Of Illinois At Chicago · F30 · FY2019 · CA
The role of UV-induced neoantigens and exogenous neoepitopes in enhancing response to immune checkpoint blockade in melanoma and other cancers.
$50,016Mack Su · Harvard Medical School · F30 · FY2019 · ES
Modeling Therapy Sequence for Advanced Cancer: A Microsimulation Approach Using Real-World Data
$50,000Elizabeth Handorf · Research Inst Of Fox Chase Can Ctr · R03 · FY2023 · HS
Re-replication of chromosomes and cancer
$50,000Anindya Dutta · University Of Virginia · R01 · FY2013 · CA
I-Corps: Translation Potential of an Immunotherapeutic Oncolytic Virus
$50,000Ian J Mohr · New York University Medical Center · · FY2024 · TIP
Modeling Therapy Sequence for Advanced Cancer: A Microsimulation Approach Using Real-World Data
$50,000Elizabeth Handorf · Research Inst Of Fox Chase Can Ctr · R03 · FY2022 · HS
Critical Issues in the Tumor Microenvironment
$50,000Rakesh K. Jain · Massachusetts General Hospital · R13 · FY2025 · CA
Mechanistic analyses of a novel RNA polymerase I transcription checkpoint
$50,000Marikki Laiho · Johns Hopkins University · R01 · FY2018 · GM
PBRM1 bromodomain missense mutations in ccRCC vascular signaling
$49,784Karina Lynn Bursch · Medical College Of Wisconsin · F30 · FY2023 · CA
Regulation of the Topoiomerase II-Dependent G2 Decatenation Checkpoint
$49,646Jacquelyn J Bower · Univ Of North Carolina Chapel Hill · F32 · FY2008 · CA
DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy
$49,538Emilia R Dellacecca · Mayo Clinic Rochester · F31 · FY2025 · CA
Computational methods for taxa-free microbial biomarker discovery and clinical risk stratification
$49,538Anastasia Lucas · University Of Pennsylvania · F31 · FY2025 · LM
Identification and targeting of metabolic profiles in cytotoxic T-lymphocyte (CTL)-resistant, HIV-infected CD4+ T-cells
$49,538Alberto M Herrera · Weill Medical Coll Of Cornell Univ · F31 · FY2025 · AI
Targeting TEAD in melanoma drug-tolerant persister cells
$49,538Connor Ott · Thomas Jefferson University · F31 · FY2025 · CA